MedTrace Logo

First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

NCT01028521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2010-07-15

No results posted yet for this study

Summary

A first time in man, phase I study to assess the safety, tolerability and pharmacokinetics of single ascending doses of CM3.1-AC100 in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

CM3.1-AC100

Solution for sc injection, single ascending doses

DRUG

Placebo

Solution for sc injection

Sponsors & Collaborators

  • CellMed AG, a subsidiary of BTG plc.

    lead INDUSTRY

Principal Investigators

  • Peter Geigle, Dr. med. · CellMed AG, a subsidiary of BTG plc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01028521 on ClinicalTrials.gov